Does the media refer more to MMED or AXGN?

In the previous week, AxoGen had 9 more articles in the media than MiniMed Group. MarketBeat recorded 16 mentions for AxoGen and 7 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.77 beat AxoGen's score of 0.20 indicating that MiniMed Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, AXGN or TFX?

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 8.60 -$15.70M -$0.68 N/A Teleflex $1.99B 2.65 -$905.64M -$23.29 N/A

Is AXGN or TFX more profitable?

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Teleflex -39.67% 11.93% 5.44%

Does the media favor AXGN or TFX?

In the previous week, AxoGen had 13 more articles in the media than Teleflex. MarketBeat recorded 16 mentions for AxoGen and 3 mentions for Teleflex. AxoGen's average media sentiment score of 0.20 beat Teleflex's score of 0.00 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Teleflex 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, AXGN or HAE?

Haemonetics has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 8.60 -$15.70M -$0.68 N/A Haemonetics $1.33B 3.47 $97.31M $2.04 49.89

Is AXGN or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to AxoGen's net margin of -13.36%. Haemonetics' return on equity of 27.55% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Haemonetics 7.12% 27.55% 9.65%

Does the media favor AXGN or HAE?

In the previous week, AxoGen had 10 more articles in the media than Haemonetics. MarketBeat recorded 16 mentions for AxoGen and 6 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.47 beat AxoGen's score of 0.20 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Haemonetics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, AXGN or ITGR?

Integer has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 8.60 -$15.70M -$0.68 N/A Integer $1.85B 2.32 $102.81M $3.66 34.59

Is AXGN or ITGR more profitable?

Integer has a net margin of 6.97% compared to AxoGen's net margin of -13.36%. Integer's return on equity of 12.79% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Integer 6.97% 12.79% 6.48%

Does the media favor AXGN or ITGR?

In the previous week, AxoGen had 12 more articles in the media than Integer. MarketBeat recorded 16 mentions for AxoGen and 4 mentions for Integer. AxoGen's average media sentiment score of 0.20 beat Integer's score of 0.05 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, AXGN or LIVN?

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 8.60 -$15.70M -$0.68 N/A LivaNova $1.39B 3.01 -$242.47M $3.38 22.46

Is AXGN or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.35% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% LivaNova 12.82% 16.35% 7.76%

Does the media prefer AXGN or LIVN?

In the previous week, AxoGen had 14 more articles in the media than LivaNova. MarketBeat recorded 16 mentions for AxoGen and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat AxoGen's score of 0.20 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AxoGen (AXGN) Competitors

$36.18 +0.14 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$36.75 +0.57 (+1.57%)

As of 07:30 PM Eastern

Compare

AXGN vs. MMED, TFX, HAE, ITGR, and LIVN

Should you buy AxoGen stock or one of its competitors? AxoGen's main competitors and comparable companies include MiniMed Group (MMED), Teleflex (TFX), Haemonetics (HAE), Integer (ITGR), and LivaNova (LIVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does AxoGen compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and AxoGen (NASDAQ:AXGN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

80.3% of AxoGen shares are held by institutional investors. 0.0% of MiniMed Group shares are held by insiders. Comparatively, 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MiniMed Group has a net margin of 0.00% compared to AxoGen's net margin of -13.36%. MiniMed Group's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
AxoGen	-13.36%	-8.90%	-6.47%

In the previous week, AxoGen had 9 more articles in the media than MiniMed Group. MarketBeat recorded 16 mentions for AxoGen and 7 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.77 beat AxoGen's score of 0.20 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiniMed Group presently has a consensus price target of $23.86, suggesting a potential upside of 24.84%. AxoGen has a consensus price target of $51.70, suggesting a potential upside of 43.45%. Given AxoGen's stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71
AxoGen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

AxoGen has lower revenue, but higher earnings than MiniMed Group. AxoGen is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.73	-$333M	-$0.68	N/A
AxoGen	$225.21M	8.60	-$15.70M	-$0.68	N/A

Summary

MiniMed Group and AxoGen tied by winning 7 of the 14 factors compared between the two stocks.

How does AxoGen compare to Teleflex?

AxoGen (NASDAQ:AXGN) and Teleflex (NYSE:TFX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

AxoGen has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

AxoGen has a net margin of -13.36% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Teleflex	-39.67%	11.93%	5.44%

In the previous week, AxoGen had 13 more articles in the media than Teleflex. MarketBeat recorded 16 mentions for AxoGen and 3 mentions for Teleflex. AxoGen's average media sentiment score of 0.20 beat Teleflex's score of 0.00 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teleflex	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 0.7% of Teleflex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AxoGen has higher earnings, but lower revenue than Teleflex. AxoGen is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	8.60	-$15.70M	-$0.68	N/A
Teleflex	$1.99B	2.65	-$905.64M	-$23.29	N/A

AxoGen currently has a consensus price target of $51.70, suggesting a potential upside of 43.45%. Teleflex has a consensus price target of $155.20, suggesting a potential upside of 24.61%. Given AxoGen's stronger consensus rating and higher probable upside, research analysts plainly believe AxoGen is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Teleflex	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

AxoGen beats Teleflex on 11 of the 17 factors compared between the two stocks.

How does AxoGen compare to Haemonetics?

AxoGen (NASDAQ:AXGN) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

AxoGen has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Haemonetics has a net margin of 7.12% compared to AxoGen's net margin of -13.36%. Haemonetics' return on equity of 27.55% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Haemonetics	7.12%	27.55%	9.65%

In the previous week, AxoGen had 10 more articles in the media than Haemonetics. MarketBeat recorded 16 mentions for AxoGen and 6 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.47 beat AxoGen's score of 0.20 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Haemonetics has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	8.60	-$15.70M	-$0.68	N/A
Haemonetics	$1.33B	3.47	$97.31M	$2.04	49.89

AxoGen currently has a consensus price target of $51.70, indicating a potential upside of 43.45%. Haemonetics has a consensus price target of $99.78, indicating a potential downside of 1.96%. Given AxoGen's higher probable upside, analysts plainly believe AxoGen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

80.3% of AxoGen shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Haemonetics beats AxoGen on 11 of the 17 factors compared between the two stocks.

How does AxoGen compare to Integer?

AxoGen (NASDAQ:AXGN) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

AxoGen presently has a consensus target price of $51.70, indicating a potential upside of 43.45%. Integer has a consensus target price of $109.86, indicating a potential downside of 13.24%. Given AxoGen's stronger consensus rating and higher probable upside, analysts plainly believe AxoGen is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has a net margin of 6.97% compared to AxoGen's net margin of -13.36%. Integer's return on equity of 12.79% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Integer	6.97%	12.79%	6.48%

In the previous week, AxoGen had 12 more articles in the media than Integer. MarketBeat recorded 16 mentions for AxoGen and 4 mentions for Integer. AxoGen's average media sentiment score of 0.20 beat Integer's score of 0.05 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Integer has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	8.60	-$15.70M	-$0.68	N/A
Integer	$1.85B	2.32	$102.81M	$3.66	34.59

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

AxoGen has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Integer has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

Summary

AxoGen and Integer tied by winning 8 of the 16 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

AxoGen (NASDAQ:AXGN) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

AxoGen presently has a consensus price target of $51.70, indicating a potential upside of 43.45%. LivaNova has a consensus price target of $87.75, indicating a potential upside of 15.57%. Given AxoGen's stronger consensus rating and higher possible upside, analysts plainly believe AxoGen is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
LivaNova	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	8.60	-$15.70M	-$0.68	N/A
LivaNova	$1.39B	3.01	-$242.47M	$3.38	22.46

AxoGen has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 0.4% of LivaNova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to AxoGen's net margin of -13.36%. LivaNova's return on equity of 16.35% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
LivaNova	12.82%	16.35%	7.76%

In the previous week, AxoGen had 14 more articles in the media than LivaNova. MarketBeat recorded 16 mentions for AxoGen and 2 mentions for LivaNova. LivaNova's average media sentiment score of 0.34 beat AxoGen's score of 0.20 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	2 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AxoGen and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.94B	$5.46B	$7.20B	$13.40B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-53.21	25.29	274.55	25.95
Price / Sales	8.64	69.02	575.97	86.00
Price / Cash	N/A	32.10	76.82	53.72
Price / Book	12.97	5.88	10.81	6.27
Net Income	-$15.70M	$146.72M	$3.50B	$382.01M
7 Day Performance	-9.37%	-0.66%	-2.02%	-1.35%
1 Month Performance	-22.51%	-4.58%	-7.53%	-5.60%
1 Year Performance	110.84%	1.17%	3.32%	-1.54%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	3.4673 of 5 stars	$36.18 +0.4%	$51.70 +42.9%	+113.3%	$1.94B	$225.21M	N/A	622	Analyst Forecast
MMED MiniMed Group	2.4084 of 5 stars	$19.74 -2.1%	$24.14 +22.3%	N/A	$5.52B	$3.10B	N/A	2,800	News Coverage Analyst Forecast
TFX Teleflex	4.375 of 5 stars	$124.71 -0.4%	$155.20 +24.4%	-1.9%	$5.28B	$1.99B	N/A	15,500
HAE Haemonetics	1.8412 of 5 stars	$103.32 -1.3%	$99.78 -3.4%	+106.5%	$4.70B	$1.33B	50.63	3,009	Trending News Analyst Forecast
ITGR Integer	2.2507 of 5 stars	$126.54 +0.1%	$109.86 -13.2%	+22.0%	$4.30B	$1.85B	34.57	11,000	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors

AXGN vs. MMED, TFX, HAE, ITGR, and LIVN

How does AxoGen compare to MiniMed Group?

Summary

How does AxoGen compare to Teleflex?

Summary

How does AxoGen compare to Haemonetics?

Summary

How does AxoGen compare to Integer?

Summary

How does AxoGen compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN vs. The Competition

AxoGen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AxoGen (AXGN) Competitors

AXGN vs. MMED, TFX, HAE, ITGR, and LIVN

How does AxoGen compare to MiniMed Group?

Do insiders and institutionals have more ownership in MMED or AXGN?

Is MMED or AXGN more profitable?

Does the media refer more to MMED or AXGN?

Do analysts rate MMED or AXGN?

Which has stronger earnings and valuation, MMED or AXGN?

Summary

How does AxoGen compare to Teleflex?

Which has more risk and volatility, AXGN or TFX?

Is AXGN or TFX more profitable?

Does the media favor AXGN or TFX?

Do institutionals and insiders hold more shares of AXGN or TFX?

Which has preferable earnings and valuation, AXGN or TFX?

Do analysts prefer AXGN or TFX?

Summary

How does AxoGen compare to Haemonetics?

Which has more volatility & risk, AXGN or HAE?

Is AXGN or HAE more profitable?

Does the media favor AXGN or HAE?

Which has better earnings and valuation, AXGN or HAE?

Do analysts prefer AXGN or HAE?

Do institutionals & insiders believe in AXGN or HAE?

Summary

How does AxoGen compare to Integer?

Do analysts recommend AXGN or ITGR?

Is AXGN or ITGR more profitable?

Does the media favor AXGN or ITGR?

Which has better valuation & earnings, AXGN or ITGR?

Do institutionals and insiders believe in AXGN or ITGR?

Which has more risk & volatility, AXGN or ITGR?

Summary

How does AxoGen compare to LivaNova?

Do analysts prefer AXGN or LIVN?

Which has better earnings & valuation, AXGN or LIVN?

Which has more risk & volatility, AXGN or LIVN?

Do institutionals & insiders believe in AXGN or LIVN?

Is AXGN or LIVN more profitable?

Does the media prefer AXGN or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AXGN vs. The Competition

AxoGen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools